Top 10 pioneering leaders redefining healthcare 2021(8) compressed

www.insightssuccess.com
VOL 10 | ISSUE 10 | 2021
Liz
Barrett
Pioneering New Treatments to Improve Patient Care
Pioneering
Leaders Rede ning
HEALTHCARE,
2021
1
Top
Compassionate
Approach
Comforting Patients
with Empathy
Chief Executive Oﬃcer
Positive Impact
Leading with
Right Skills

Rising to
Every
Challenge
Editor’s Desk
or any civilization, the availability of functional and
Feffective healthcare systems is the most fundamental
and is a question of life and death. The time of
pandemic was challenging for all fields, but it was
especially more challenging for the healthcare field and
healthcare leaders. It put the role of healthcare leaders to
the test. However, it brought out the best in healthcare
leaders.
Healthcare leaders stood up bravely to respond to the
challenge of the pandemic. They learned a lot of crucial
lessons in the pandemic and, today, are continuing to play
an instrumental role in strengthening the healthcare systems
for ensuring the better health of people in the world.
Covid crisis has led to the need for reforms in healthcare
systems for better service of patients. It highlighted the
need for sustainable and responsive healthcare systems.
Healthcare leaders are removing the loopholes in the
systems and are also focused on building a strong physical
infrastructure of healthcare systems along with the most
capable and trained healthcare professionals. They are
addressing every underlying issue that needs to improve the
functionality of the healthcare systems.
Healthcare leaders responded to the challenge of the
pandemic with an innovative approach and more urgency in
their actions. With their research and innovative abilities,
they are coming up with pragmatic and innovative solutions
not just for dealing with the pandemic but also to deliver
sustainable healthcare solutions to the people. There is
enough evidence that healthcare systems that have the
ability to deliver services efficiently and equitably are most
important for achieving the improved health status of
maximum people in the world.
A sound healthcare leader prepares a strategy for tracking
the performance of healthcare systems, evaluating impact,

and ensuring accountability. He or she depends on
sound and reliable information for making the most
important decisions to enhance the capabilities of
healthcare systems.
In the current scenario, healthcare leaders are
revolutionizing the healthcare industry. They are
playing an important role in making sure that
patients have access to essential medicines all the
time. They are creating solutions that will be
accessible and affordable to everyone and are trying
to reduce health inequity. They are governing
healthcare systems with a very organized and
responsible approach.
In this edition of “Top 10 Pioneering Leaders
Redefining Healthcare, 2021,” we have compiled a
list of those leaders who, with their deep knowledge,
compassionate approach, and exemplary skills, are
delivering quality, accessible, and affordable care to
people.
On the cover, we have Liz Barret, the CEO of
UroGen Pharma. As the leader of UroGen, a
biopharmaceutical company that pioneers innovative
therapies to revolutionize care for patients with
urothelial and specialty cancers, Liz knows what it
takes to create a paradigm shift for treating life-
threatening diseases. She has been responsible for
introducing oncological treatments to market in the
U.S. as well as abroad, and has always been driven
by what’s mattered most—passion and purpose.
Let’s unveil more alike and inspiring stories of such
pioneering leaders and spread the word about their
contribution to making this world a better place.
Let’s start reading!
sharad@insightssuccess.com
Sharad Chitalkar

CONTENTS
Cover
Story
Pioneering New
Treatments to
Improve Patient Care
Liz Barrett
08
Articles
Compassionate
Approach
Comforting Patients
with Empathy
Positive Impact
Leading
with Right Skills
44
28

Jerry Lepore
Changing Healthcare,
One Life at a Time
40 Jim Bob Ward
Empowering Clinical Teams
with Innovative and End
User Friendly Solutions
48 Jon Zimmerman
Combining Technology
and Innovation to
Streamline Healthcare
52
Ardy Arianpour
A Visionary Tech Leader
Pioneering the
Experience of Healthcare
16 Arnaud Mascarell
Trailblazing the Eﬀective
and Innovative
Technology in Healthcare
20
Helmy Eltoukhy
& AmirAli Talasaz
Conquering Cancer
with Data
32 Javier García
Developing Strategies
for Life-Saving
Therapeutics
36
David H. Mowry
Creating the Future of
Medical Aesthetics by
Aligning Company Leaders
Around a Singular Vision,
Goals, and Objectives.
24

sales@insightssuccess.com
October, 2021
Editor-in-Chief
Senior Sales Manager Business Development Manager
Marketing Manager
Technical Head
Technical Specialist Digital Marketing Manager
Research Analyst
Database Management Technology Consultant
Hitesh Dhamani
Managing Editor
Anish Miller
Assistant Editors
Jenny Fernandes
Visualizer
David King
Art & Design Director
Priyanka Rajage
Associate Designer
Kshitij S Peter Collins
John Matthew
Sales Executives
David, Martin, Mehboob
Business Development Executives
Steve, Joe, Akash
Jacob Smile
Aditya Marry D'Souza
SME-SMO Executive
Amol Wadekar Frank Adams
Circulation Manager
Robert Brown Stella Andrew David Stokes
Kartik Balapurkar
Co-designer
Copyright © 2021 Insights Success, All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any
form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success.
Reprint rights remain solely with Insights Success.
Follow us on : www.facebook.com/insightssuccess/ www.twitter.com/insightssuccess
We are also available on :
Shubham Dali
Executive Editor
Sharad Chitalkar

Brief
Company Name
Datatrak
datatrak.com
Jim Bob Ward
CEO and President
Datatrak International is the first EDC provider, first SaaS
cloud provider and the first eClinical suite built on an
Enterprise platform.
Seqster
seqster.com
Ardy Arianpour
CEO and Co-Founder
Seqster is a SaaS-based healthcare technology company.
Jerry Lepore
CEO
MobileSmith Health
mobilesmith.com
MobileSmith Health is a leader in the digital health and mobile
development sector.
Helmy Eltoukhy &
AmirAli Talasaz
Co-CEOs
Guardant Health
guardanthealth.com
Guardant Health is a leading precision oncology company.
Aspira Womens Health
aspirawh.com
Kaile Zagger
COO
Aspira Women's Health is committed to solve women's health
issues for all ethnicities, stages, and ages
Jon Zimmerman
CEO
Holon Solutions
holonsolutions.com
Holon Solutions is dedicated to remove administration burden
from providers.
Arnaud Mascarell
Co-Founder and CEO
FineHeart
fine-heart.com
FineHeart is a French medical device company focused on
creating innovative technologies in the cardiovascular field.
David H. Mowry
CEO
Cutera
cutera.com
Cutera, Inc. is a leading global aesthetics device company.
Liz Barrett
CEO
UroGen Pharma
urogen.com
UroGen, is passionate about making a difference for patients
with urologic diseases.
Javier García
CEO
Viralgen was created in response to the unmet need for
manufacturing of gene therapies.
Viralgen Vector Core
viralgenvc.com
Featured Person
Pioneering
Leaders Redefining
HEALTHCARE,
2021
1
Top
Top

Liz
Barrett
Pioneering New Treatments to Improve Patient Care
Innovative technology
for transformative
treatment.
‘‘
‘‘

ood health is central to human happiness and well-
Gbeing. It is vital to our ability to not only survive
but thrive, as most recently evidenced through an
unprecedented global pandemic. In addition to calling our
collective attention to a brand-new health risk, people all
over the world were confronted with the need to rethink
their outlook on health altering the delivery and access to
optimal care. The recognition of the healthcare system as an
engine for innovation has grown, and awareness of the need
for scientific innovations has never been greater, especially
in our ongoing battle with some of the most evasive
illnesses in the world—i.e., cancer.
Now in a new technology-driven era, there emerges new
hope, new modalities and perhaps a new way to treat
certain cancers in ways we never could before. It very well
may be the dawn of a new era in cancer treatment, if Liz
Barrett, CEO of UroGen Pharma, has anything to say
about it. As the leader of UroGen, a biopharmaceutical
company that pioneers innovative therapies to revolutionize
care for patients with urothelial and specialty cancers, Liz
knows what it takes to create a paradigm shift for treating
life-threatening diseases. Liz totes a celebrated career,
having held business lead and executive positions at some
of the world’s leading healthcare companies. She has been
responsible for introducing oncological treatments to
market in the U.S. as well as abroad, and has always been
driven by what’s mattered most—passion and purpose.
We sat down with Liz to get a better understanding of what
she believes is next for UroGen and for the future of cancer
care.
When Passion and Purpose Come Together
Liz Barrett is characterized by some very distinctive
qualities. She is known to be decisive, committed and
courageous. Those closest to her might also add that she
values and delivers clear communication, no matter how
big or small the conversation, that she challenges
conventional thinking and encourages others to be bold and
solution-oriented and that she has a penchant for seeking
out and overcoming challenges. Above all else, she is
collaborative and passionate about her work in driving
scientific innovations to help treat more cancer patients.
There is no doubt that her passion, drive and persistence in
meeting challenges head on propelled her upward trajectory
throughout her three decade-long career in healthcare.
Having begun her career in the Consumer Goods business
unit of Johnson & Johnson, Liz soon realized her true desire
was to work in the company’s pharmaceutical division,
where she could make a bigger impact on society and the
well-being of others. Liz identifies this as the moment she
became truly passionate about oncology, as cancer is a
Liz Barre
Chief Execu ve Officer
UroGen Pharma

disease that in one form or another, touches almost
everyone. Then, the 5-year survival rate for patients was
low, but innovation in this field and new treatments over the
last couple of decades have helped spark better outcomes
for patients and also better quality of life. The
pharmaceutical industry has moved away from toxic
chemotherapies as the standard of care, and instead, toward
targeted agents, focused on immune-oncology as much as
possible.
And much of this, Liz says, has been made possible by
technology.
Paving a Better Path for Patients with Technology
Admittedly, ‘technology’ is a very broad term these days.
It’s not just a road to our future but a baseline language and
connector as well. At UroGen, there also exists a duality to
this term. On the one hand, there are the medical therapies
that utilize new and advanced technologies such as
UroGen’s RTGel™ (Reverse Thermal Gel) technology
platform, and then there is technology that allows them to
communicate and educate stakeholders across the
continuum, hopefully expediting the identification of
patients and the execution and support needed for
practitioners to utilize UroGen’s innovative treatments.
In recent years, UroGen achieved a breakthrough milestone
in cancer treatment with its RTGel technology platform, a
proprietary hydrogel-based formulation that has the
potential to improve the therapeutic profiles of existing, as
well as new, drugs. This remarkable, sustained-release
technology is stored in liquid form and transforms to a gel
once administered into the body. The technology is
designed to enable longer exposure–known as “dwell
time”– of the urinary tract tissue to medications, making
local therapy a potentially more effective treatment option.
UroGen’s first FDA-approved therapy using the novel
®
RTGel technology, Jelmyto (mitomycin) for pyelocalyceal
solution, received breakthrough FDA approval in April
2020 and is the first and only treatment of its kind for adult
patients with low-grade upper tract urothelial cancer (LG-
UTUC).
Urologic cancers are devastating types of cancer, often
affecting elderly people, with high recurrence rates. The
Making the
Impossible
Possible.
‘‘
‘‘

Driven to
create
lasting
change for
our patients.
‘‘
‘‘

standard of care for these types of cancers is typically
multiple surgeries, imposing significant burdens on elderly
patients and the healthcare system overall. As Liz says,
"you don't really cure these diseases; you manage them."
Keeping this understanding as a mantra, Liz remained
unwavering in her focus on leading her team through a
successful product launch in 2021, at the height of the
COVID-19 pandemic.
Answering an Unmet Need in Cancer Treatment
UroGen does what it does for one simple reason, because
patients deserve better. Their novel, proprietary
technology allows necessary medicines to be delivered
locally, and then to disintegrate and void naturally. In other
words, UroGen delivers more effective treatments to
urothelial cancer patients without the risks and
uncomfortable side effects of traditional therapies.
This is especially important considering certain urologic
and specialty cancers, such as LG-UTUC, impact people of
advanced age, which makes it difficult and risky to undergo
and recover from multiple surgeries that take a substantial
toll on their quality of life.
UroGen strives to advance the development of highly
effective, non-surgical treatment options that alter the
course of disease and fundamentally change the patient
journey.
Building a Patient-Centric Company
It was this spirit of patient centricity that attracted Liz to
lead this organization, which had 70 employees in 2019 and
has grown to more than 200 in 2021. “I was very impressed
with the culture and importantly, the attitude of the team at
UroGen when I joined,” she says. Liz is committed to
fostering this culture, providing clear direction and
supporting her team’s professional and personal aspirations.
“Our current values of Act Boldly, Be Inventive and Stay
Connected were driven by what the team was already doing
and the environment we wanted to create.”
When faced with an idea or opportunity, Liz encourages her
colleagues to have an open mindset, to challenge each other
in a healthy way, and to think about how the team can
continuously build upon past successes to drive and bring
innovative therapies to patients around the world. It is the
patient success stories, Liz says, that truly inspire and
motivate my colleagues to do more to improve health.
What’s Next at UroGen?
Guided by Liz’s vision and leadership, UroGen continues to
explore avenues to accelerate the development of truly
innovative medicines that advance the standard of care in
uro-oncology and beyond. The company is committed to
working in areas of high unmet need, such as LG-UTUC
and other specialty cancers, where they can make a real
difference in the lives of millions of patients that are
impacted by these illnesses.
The vision for UroGen’s future includes ambitions of
continuing to partner with leading, world-class institutions
to explore the full potential of its RTGel platform across
various disease states. Earlier this year, the company
announced an exploratory immunotherapy-sponsored
research agreement with Johns Hopkins University to study
the potential of checkpoint inhibitors combined with RTGel
in glioblastoma multiforme, or GBM, an aggressive and
difficult-to-treat brain cancer. The company also recently
announced a strategic research collaboration with MD
Anderson to advance UroGen’s investigational treatment,
UGN-302, for high-grade bladder cancer, potentially
bringing next-generation immunotherapy to these patients
with a significant unmet need and limited clinical options.
"You need to have the flexibility to be able to follow where
the medicines are and what science tells you, and then go
that way. It's like you have no better opportunity in your life
than to have an impact on human health. So, hang in there,
don't get discouraged, and follow the science.”
Advice to the Leaders of Tomorrow
According to Liz, the healthcare industry is the best place to
be, although she acknowledges that it’s a challenging
industry to navigate. If she could provide advice to other
women in the industry on how to succeed, it would be this:
“Don’t underestimate your impact…both positive and
negative. Focus the team on what is important; stay true to
yourself but recognize you have the ability to create an
environment for others to bring their best self. And if they
do that, we all win because that is when the best things
happen for patients and the business success will follow.”

Ardy Arianpour
CEO and Co-Founder
Seqster
Top 10 Pioneering Leaders Redening Healthcare, 2021
16 | October 2021 www.insightssuccess.com

ARDY
ARIANPOUR
Visionary HealthTech Leader Delivering Patient
Experience and Transforming Healthcare
In today's world, data is one of the most critical assets that one can
possess to improve and innovate in almost every industry. Leading
professionals who understand the value of data have discovered
technologies that can flourish over time, and the healthcare industry isn't an
exception. These leaders are developing technologies for organizations to
drive accurate and efficient healthcare via data. Ardy Arianpour, the CEO
and Co-Founder of Seqster, is one such leader who is on a mission to make
patient-centric interoperability a reality and lead the nation with his venture.
We at Insights Success caught up with Ardy Arianpour in our endeavor to find
the "Top 10 Pioneering Leaders Redefining Healthcare, 2021" and
interviewed him to share his expertise and how he is bringing a meaningful
difference to the healthcare world.
Below are the highlights of the interview.
Brief our audience about your journey as a business leader until your
current position at Seqster. What challenges have you had to face to
reach where you are today?
My journey as an immigrant to the USA began at the age of 6 in 1986. Fast
forward to the 2000s, when I became a young executive, and then leading to
my position as CEO/Founder of Seqster from 2016. I'm used to challenges. I
thrive in uncertainty because I have a strong sense of purpose, and the same
can be said about my company; Seqster's mission is centred on breaking
down data silos to improve patient lives at scale, which is the biggest
healthcare challenge. To do this, we focused on how to create a platform to
put the data in the patient's hands, empowering them to collect, own and
share their data on their terms.
17
|
October 2021

Ironically, the first patients we were able to help were my
grandmother, who suffered from Alzheimer's Disease, and
my father who was diagnosed with colon cancer. I
witnessed firsthand the impact of the Seqster platform for
not only the patient but for the entire family's care journey.
Seqster makes health data access seamless and easy to share
in a highly private and secure manner.
What is really remarkable is that for most companies, their
vision is in a distant future, far, far away. At Seqster, we
executed our vision early in 2018, while delivering on our
mission by setting the standard for patient-centric
interoperability and real-time data access.
Enlighten us on how you have made an impact in the
healthcare niche through your expertise in the market.
I knew early on that DNA/genomic data is meaningless
unless it is paired with high-quality, high-fidelity medical
record data. Health records have been a static snapshot that
captures a person's health profile at one point in time. A
dynamic, real-time view of health is critical for better
monitoring of health conditions and more timely medical
interventions. Seqster has automated the collection of
longitudinal health records, and further, we have created the
first and only platform that ties together DNA,
fitness/wearable, and health records data in one place.
My career has
always been
focused on
empowering
patients. We are
all patients at
one time or
another.
“
“
18 www.insightssuccess.com
| October 2021

The stars have aligned at the right place and at the right
time. There is a massive push towards healthcare
consumerization, simplifying the patient experience and
improving the patient journey. The focus is increasingly on
the patient, from the latest patient access and
interoperability guidelines worldwide to how the
information is intuitively displayed for the patient, their
physician, and the care team to readily understand. My
career has always been focused on empowering patients.
We are all patients at one time or another.
What people, what books, what life factors have
influenced and impacted you?
Steve Jobs inspired me at a very young age as a visionary
entrepreneur who made Apple what it is today. I was also
inspired by Bill Gates when I met him in 2018 after being
asked to deliver a private presentation, in which he
suggested that we take Seqster enterprise in order to scale.
As far as books go, his monumental book Business @ the
Speed of Thought taught me the importance of trusting my
instinct and executing quickly. Additionally, both my
maternal and paternal grandmothers suffering from
Alzheimer's led me to realize how important multi-
generational data is for society.
We have had special requests from patients to use our
platform. After granting access, we realized how life-
changing being on the Seqster platform is. When my father
was sick with colorectal cancer, I was able to get him
diagnosed immediately and in surgery in days instead of
weeks by running a tumor board in 6 hours with his health
data. These personal stories, as well as remarkable stories
from patients who have used the Seqster platform, keep our
team working hard every minute of every day.
Describe in detail the values and the work culture that
drives Seqster.
Everything we do at Seqster is patient-first, which means
we run a culture that is fast-paced, passionate, and
engaging. We are a nimble ninja team that is used to
executing quickly and effectively. When it comes to either
the patient or how I run the company, there is no "Plan B."
We strive for excellence in everything that we do. Failure is
not an option because our mission is so critical that I never
have a "Plan B." We only go by "Plan A.”
What is your opinion on the necessity for businesses to
align your offerings with newer technological
developments?
Seqster aligns well with the newer technologies, such as
virtual care, specialty pharmacies, and virtual clinical trials
that require a longitudinal 360-degree view of the patient's
health. A static snapshot of a person's health does not tell a
complete story. Seqster provides a real-time, dynamic view
that is unique in digital health and healthcare.
Where do you envision yourself to be in the long run,
and what are your future goals for Seqster?
In the long run, I could see our technology at Seqster
impacting patient lives at scale in the same way that
Amazon or Netflix has made it seamless for consumers to
order a product or watch a movie. I couldn't be more
excited about what lies ahead. We are just getting started
and are in hyper-growth mode.
What would be your advice to budding entrepreneurs
who aspire to venture into healthcare?
Entrepreneurship is one of the most challenging and
rewarding things that you can do with your life. When you
layer in healthcare, on top of how challenging
entrepreneurship is, it feels impossible most of the time.
The only way that you can get through the tough times is by
fully aligning with the mission. My advice is that if you
want to venture into healthcare, make sure that you are
100% committed to your mission. If not, I guarantee you
will fail. The mission is the soul of the company and is a
must-have.
19
www.insightssuccess.com |
October 2021

Arnaud Mascarell
Co-Founder and
Chief Executive Oﬃcer
FineHeart
| October 2021

Trailblazing the Effective and Innovative
Technology in Healthcare
Heart failure is one of the major diseases the current
world faces. To avoid such mishaps, people
nowadays are becoming more and more health-
centric. The saying goes, "With a healthy heart, the beat
goes on." However, heart failure can lead to various
dreadful consequences, and the treatment process is even
more complex. To address the ongoing need for innovation,
Medtech companies continue to develop devices to improve
the heart's pumping capacity. However, most options risk
internal damage to the heart. FineHeart has developed an
innovative device that provides temporary and permanent
support for this crisis to prevent internal damage.
One of the brains behind FineHeart is Arnaud Mascarell,
the Co-founder & Chief Executive Officer. Arnaud leads
with a charge and has defined groundbreaking strategies to
make FineHeart a well-known and esteemed organization in
healthcare. He utilizes his immense experience to ensure
the clinical development plans are on track to fulfill the
FDA requirements and other competent authorities.
A Fine Journey to the Heart
When Arnaud received his Biomedical Engineer degree
from UTC (Technological University of Compiègne,
France), he started as a research engineer at Air Liquide
Santé. After serving a brief period, he later joined
Medtronic as a Field Clinical Engineer. He quickly realized
that he would also have to explore the business side of
medical operations to expand his skills. Arnaud went on to
pursue an MBA from IAE Paris in 2000. His decision came
to fruition as the degree reoriented his career, and he began
to focus on sales and marketing. After a decade, he jumped
into his entrepreneurial journey and co-founded FineHeart
in 2010.
Utilizing Technology for Competitive Lead
According to the World Health Organization, heart disease
has remained the leading cause of death globally for the
past 20 years. Arnaud mentions that the second leading
cause of death in the United States and Europe is heart
failure. It has become a global pandemic affecting an
estimated 64.3 million people worldwide, with a steadily
rising incidence (over one million new cases in G8
countries). Heart Failure is a degenerative disease where the
heartbeat weakens over time, becoming more and more
severe. This results in reduced quality of life, frequent,
costly hospitalizations, and early mortality. A quarter of
problems are electrical, which can be treated with pacemak-
ers. The other two-thirds are muscular, which can ultimately
only be resolved with a heart transplant.
The shortage of donors limits heart transplants, so a device
called an Left Ventricle Assist Device (LVAD) is implanted
to improve the pumping capacity of the left ventricle.
Despite the urgent need, current LVADs are bulky, which
causes significant myocardial damage. They are associated
with a risk of infection, bleeding, and thrombosis, which is
why they are almost exclusively implanted on very severe
patients with short life expectancy. In the event of a
cardiogenic shock, it is often necessary to wait to decide
21
Top 10 Pioneering Leaders Redefining Healthcare, 2021
|
October 2021

whether to implant an LVAD and force physicians to resort
to temporary circulatory assist solutions.
FineHeart has invented a breakthrough device called the
ICOMS FLOWMAKER®. This device can provide both
temporary support (with no time limit and preserving the
patient's mobility) and permanent support if the patient does
not recover sufficiently from the shock, which constitutes a
paradigm shift in how severe Heart Failure patients will be
treated.
The ICOMS FLOWMAKER® is like an electric bicycle, as
it increases the blood flow and is synchronized to the
natural heartbeat.
The entire ICOMS FLOWMAKER® system is fully
implanted in the left ventricle. It is powered by a miniatur-
ized internal battery that is rechargeable by transcutaneous
energy transfer (TET). It eliminates the risk of driveline
infection, a significant determinant of post-VAD morbidity
and mortality. Maintaining trans-aortic flow supports
increases left ventricle unloading, improving myocardial
recovery chances and faster device weaning possibilities.
The wireless device is programmable, like a pacemaker, and
the operating modes can be customized for individual
hemodynamic requirements, which preserves pump
efficiency in case of increased cardiac demand.
According to the patient's point of view, ICOMS
FLOWMAKER is designed to deliver improved quality of
life by providing untethered freedom and supporting the
patients' return to daily activities.
Overcoming Severe Challenges
One of the biggest challenges that doctors face is the lack of
long-term treatments for heart failure patients, especially
those who have progressed to the most severe stage of the
disease. These patients bear the brunt of the economic
burden, but most treatments do too little to help them.
FineHeart is determined to disrupt the deadly cycle of heart
failure and address the unmet needs of patients. ICOMS
FLOWMAKER is the only device that will preserve the
heart's natural pumping function, as it synchronizes with the
heartbeat to augment blood flow.
Stepping Up in Tough Times
Discussing the impact of the COVID pandemic, Arnaud
expresses that the issue with the pandemic is that it has
monopolized the health community. However, with heart
failure being a degenerative disease, patients' treatment
delays have worsened the condition.
“Addressing the unmet need of
patients with severe heart failure.”
| October 2021

Fortunatey, FineHeart has been able to continue developing
its device through pre-clinical trials and has not been overly
impacted. His concern with the pandemic is that numerous
patients have suffered heart problems with severe forms of
COVID-19, which could lead to a higher risk of severe
heart failure in the future.
Over the Horizon
Moving ahead and chasing milestones, Arnaud's efforts
have helped FineHeart recently close an $18M series B
funding. This financing was accomplished with a pool of
industrial and independent investors. The collective action
brought together know-how from the world of technologi-
cal excellence and renowned medical expertise, shown by
the substantial contribution from cardiologists, who
individually invested. This consortium of shareholders
represents a new approach, going beyond the cookie-cutter
approach to secure financial support.
It is one example of how FineHeart will continue to push
and find innovative ways to deliver the disruptive treatment
that the ICOMS FLOWMAKER embodies. The organiza-
tion now holds all necessary resources to ramp up develop-
ment and is on track to target First-In-Human clinical trials
next year.
Follow Your Heart
FineHeart faces all the challenges of a start-up in the
Medtech Industry, from R&D and product trials to the
difficulties of raising finance regularly. Arnaud understands
the entrepreneurial drive and the challenges, so he advises
up-and-coming entrepreneurs to believe in their products.
"If you believe in your product and the potential disruptive
treatment it can bring to save patients' lives, you must keep
going and find solutions," says Arnaud.
23
October 2021

David H. Mowry
Creating the Future of Medical Aesthetics by Aligning Company
Leaders Around a Singular Vision, Goals and Objectives
t is nearly impossible for organizations to sustain great
Iresults without alignment among leaders. To achieve
alignment, leaders of successful organizations
willingly put company and team goals ahead of their own.
Aligning leaders and helping them achieve a singular focus
is one of the most crucial responsibilities of any chief
executive. This focus is what accelerates the path forward
to organizational efficiency, effectiveness, and excellence. A
common trait among pioneering leaders is the ability to
transform the culture of their organization by remaining
true to top priorities, which in turn enriches employees,
delights customers, and creates value for shareholders.
David H. Mowry is one such pioneering healthcare leader
who likes to create a culture where the team is aligned to a
singular shared set of goals and objectives. David is the
CEO of Cutera and is a seasoned executive with history of
success in the Medical Device space and a proven track
record of execution and transformational results.
In an interview with Insights Success, David shared about
his journey and his contribution through Cutera.
Below are the Highlights of the Interview:
Please brief our readers about the composition of the
leadership team at Cutera.
Cutera is a story about execution, and the most critical
indicator of execution is having the right leadership team in
place. So, my highest and most urgent priority upon joining
was the installation of a reliable and unified leadership team
committed to a singular value creation game-plan.
The incumbent leadership structure lacked two main
ingredients; 1) technical excellence in several critical
functions and 2) leaders aligned and committed to
subordinating their personal goals for the benefit of the
company's goals. Since my arrival in the summer of 2019,
we have turned over nearly 85% of the senior leadership
team. Our focus in recruiting new leaders was first on
functional competence and subsequently on collaboration
and teamwork. The result of the process has given Cutera
an amazing group of committed senior leaders who have
earned one another's respect and who provide commitment
and support.
Describe the company, its innovative medical aesthetics
products, how it is differentiated in energy-based
aesthetics, and how Cutera meets the needs of the
customer.
Cutera was founded by veteran laser engineers and the
spirit of innovation continues to drive the business.
Somewhere along the way, our approach to innovation
shifted to that of a fast follower, where our devices brought
increased capabilities, but also greater complexities and
costs. To correct this, we have made two fundament shifts:
first, we innovate to great value – either "better outcomes at
same costs," or "same outcomes at lower cost," or, most
appealing, the homerun of "better outcomes at lower costs."
Our second shift is that we are moving away from over-
engineered, fast-follower devices to being first to market for
unmet clinical needs.
What were the challenges you came across since joining
the organization?
There have been both micro and macro challenges.
Certainly there is the obvious macro challenge presented by
the COVID-19 Pandemic. Cutera, like others, needed to
take significant and immediate action to survive, which we
did. Looking back, I am very pleased with our efforts
during this time as we not only survived the challenge, but
we also emerged leaner, better aligned and more focused on
our customers. We strengthened our balance sheet while
also upgrading our commercial talent. As for micro
challenges, we had weak supply chain and high costs which
| October 2021

David H. Mowry
CEO
Cutera
25
October 2021

have been significantly improved through our margin
expansion programs, improving profitability and enabling
great reinvestment into our business to fuel longer term
growth.
How would you describe your leadership style and how
is that impacting the people at Cutera?
I spent some time in the Army after getting my
undergraduate degree and I learned two things very quickly:
first, that it is possible to learn something from everyone.
Humility is a catalyst for open exchange of ideas and
almost always surfaces the best solution to a problem. The
second take-away for me was the value of people. People
are and will always be the most critical resource. We should
always respect our teams and employees, which includes
sharing the data, actively communicating, empowering
them, and allowing them to fail from time to time. Some
other related leadership style tidbits that guide my style
include the idea that you only fail when you stop trying. I
also believe leaders should take the time to recognize effort
and whenever possible, publicly reward results. Another
belief I hold dear is that perfect is often the enemy of good,
and that we must take our gains now and keep moving
forward.
Describe in detail about the work culture and the values
that drive the company
At Cutera, we have adopted a series of what we call
Transformative Values with the belief that embracing and
incorporating these values into who we are and what we do
will accelerate our advance toward our shared goal of
"Creating the Future of Medical Aesthetics." These values
are taking hold and helping drive the culture we seek. These
values include:
1. Aligned – Working as a singular team to a shared set of
goals/objectives.
2. Bold – Stretching outreach, expanding our impact.
3. Data-Driven – Using data versus opinions to settle
disputes increases alignment.
4. Focus – Doing fewer things, better.
5. Fun – Enjoying the work you're assigned and the people
you're working with.
What would be your advice for emerging business
leaders aspiring to venture into the healthcare industry?
I have found my 30-plus year career in medical devices and
healthcare to be enriching because of the ability to
participate in some small way within the value stream of
improving the quality of life for others. We have all heard
the phase, "do what you love, and you will never work a
day in your life." I have found this saying to be true for
each of my assignments in the healthcare industry,
regardless of sector, business structure (public or private) or
company maturity (start-up or large cap strategic company).
I can't imagine leading a company outside healthcare.
How do you sustain in the current unpredictable market
and hectic competition?
There is no doubt that this a hectic and competitive
environment coming out of COVID-19, but companies and
leaders need to stay the course by continuing to listen to
customers and employees and providing differentiated
offerings that bring value. And sometimes just slowing
down and doing what is right can calm the pace, refocus the
team, and relieve pressures that are not constructive to the
process.
What is future vision for the company? And what would
be the best roadmap for getting there?
At Cutera, we have a clearly stated vision, which is to
"Create the future of Medical Aesthetics." This includes
being the partner of choice for our core customers, which
are dermatologists, plastic surgeons and "med spa"
physicians. Doing so ensures we stay focused on the right
conditions, we look for first mover opportunities to meet
unmet clinical needs, and we provide our offering as a true
partner. As we speak, all of Cutera is well along on this
journey.
Cutera is a leading global
aesthetics device
company with a
comprehensive product
portfolio and a global
distribution footprint.
“
“
| October 2021

Comforting
Patients Empathy
with
Compassionate Approach
| October 2021

people empathetically, give them much comfort, and
minimize their pain. Empathy can make a significant
difference in the lives of people's physical, mental,
emotional, intellectual, and spiritual levels. The healthcare
leaders should invest in educating and training healthcare
professionals in developing empathy and other important
qualities to serve the patients better and help them feel
better on all levels.
Healthcare companies can have tangible business results if
they try to deliver their services empathetically to the
patients. The empathy in healthcare leaders and
professionals will help them develop more patient-centric,
innovative, and modern solutions for the better treatment of
patients. When patients are treated with empathy, it builds
trust. Empathy in healthcare leads to better patient
outcomes, better patient compliance, better patient
satisfaction. Empathetic leaders are better able to
communicate with patients and have improved and
intellectual perception of the emotional state of patients.
With more relatedness and understanding of patients, they
can suggest the best course of action to free them from their
pain or illness.
When physicians treat patients with a high degree of
empathy, they naturally feel much better, and their panic
level decreases. Studies show that the diabetes patients
treated with empathy showed a significantly reduced rate of
metabolic complications. When patients are treated with
such a high level of empathy, they feel much better, and
such patients recommend the company's services positively
to other people. Naturally, the customer retention of
healthcare companies increases to a great extent and can
lead to greater profitability and an opportunity to serve
more people in the coming times. Leading with empathy
increases the credibility and trustworthiness of healthcare
companies, and they can make a huge difference in patients'
lives by treating them empathetically.
Empathy and compassion play vital roles in every
relationship within the social and professional
circles. It is the ability that helps people to
understand better and try to encourage and comfort others.
The emotional intelligence of a person plays a significant
role in behaving empathetically with others. Empathy is an
essential quality that healthcare professionals should have
as they directly deal with patients suffering from pain or
illness.
The importance of empathy is much more than in
healthcare than in any other industry. Healthcare
professionals pay meticulous attention to ensure that the
empathetic culture is ingrained in their organizations to
deliver proper treatment to the patients with care. Empathy
and compassion cannot be separated from each other, just
like sweetness cannot be separated from sugar.
Comforting the afflicted people is the most crucial, and it is
not as easy as it sounds. The more one understands oneself;
the more one will understand others. How healthcare
leaders present things or how they deliver services to
patients through their healthcare companies is critical.
Healthcare leaders should promote the culture in their
companies so that they sensitively deal with patients and
minimize the pain and suffering of patients.
Clinical empathy has more to do with a detached mode of
understanding with patients. At times medical professionals
are more practical and rational. Clinical empathy is not an
emotional but an intellectual understanding of patients'
emotions so that they can forge a proper solution. They
understand it is stressful and disempowering to be sick.
Therefore, healthcare professionals should empathetically
deal with patients to minimize their stress and reenergize
them.
In people's lives, at some time, suffering is inevitable due to
unavoidable circumstances, but the pain is optional.
Someone who has good counseling skills can deal with
29
October 2021

Conquering Cancer with Data
Helmy Eltoukhy
& AmirAli Talasaz
The battle against cancer has been fought for years,
and healthcare leaders have continuously tried to
come up with new and reliable solutions.
Innovative technologies are constantly being developed and
improved upon to find feasible ways to detect and treat
cancer, including at its earliest stage. Two pioneers in the
fight against cancer are Co-Founders and Co-Chief
Executive Officers of Guardant Health, Helmy Eltoukhy
and AmirAli Talasaz.
Helmy and AmirAli are both serial entrepreneurs in the
biotech field and have known each other for about two
decades, even working in the same lab in their graduate
school at Stanford. They shared the belief that applying
ultra-high-scale DNA sequencing to the clinical markets
could fundamentally improve the trajectory of patients’
healthcare journeys. They co-founded Guardant Health in
2012.
The dynamic duo of Helmy and AmirAli believes that the
key to conquering cancer is to expand efforts to detect the
cancers most likely to be cured through early intervention
and access to their molecular information throughout all
stages of the disease.
Helmy Eltoukhy
Ph.D, Co-Chief
Execu ve Officer
Guardant Health
AmirAli Talasaz
Ph.D, Co-Chief
Execu ve Officer
Guardant Health
| October 2021

The Inception Overview
Cancer being a disease of the genome made it an area
where DNA sequencing could make a significant impact if
cancer could be found early enough and tracked in real-time
through a simple blood-test. This idea became Guardant
Ò
Health, and its first product, Guardant360 , was launched in
2014. One challenge Helmy and AmirAli have had to
overcome is making this new technology, liquid biopsy,
accepted in the industry given that tissue biopsy had long
been the standard of care. At Guardant Health, their now
widely used liquid biopsy tests aim to transform cancer care
management across all stages of the disease.
Their Guardant360 CDx test is the first FDA-approved
comprehensive liquid biopsy for patients with advanced
cancer, and now the company sets its sights on potentially
bringing to market the first FDA-approved blood test for
cancer screening with the potential to increase the cancer
screening.
Since founding the company, Helmy and AmirAli have
scaled the company to almost 1,500 employees and
launched multiple commercially available products across
the cancer care continuum.
The Mission and Vision
Helmy states that the mission of Guardant Health is to
conquer cancer with data. Since day one, their vision has
been to develop a simple blood test that screens for cancer
at its earliest and most treatable stage. To get there, the
company has taken a beachhead strategy starting first where
the greatest unmet medical need exists – advanced cancer –
and where the DNA shed from a tumor into the blood is
easier to detect.
Helmy says, "Our company's blood tests for cancer
profiling and monitoring are easier, faster, and less invasive
than traditional tissue biopsy-based approaches. Our tests
enable physicians to stay one step ahead of a patient's
cancer at all stages of the disease and help identify the
latest breakthrough treatments, which are increasingly
targeted to the molecular makeup of the tumor and much
better tolerated than traditional ‘one size fits all’
chemotherapy.”
AmirAli expresses that they are closer than ever to
achieving the goal of providing a simple blood test that
screens for cancer at the very earliest stage, among average-
risk, asymptomatic people.
"We are excited with our progress in our historic ECLIPSE
trial with over 10,000 participants, which is evaluating the
performance of our blood test to detect the earliest signs of
colorectal cancer, and if successful, will support our
submission to the FDA. The promise of blood-based cancer
screening is quickly becoming a reality, and we see a
brighter future for humanity by improving population health
and reducing the harms of cancer," says AmirAli.
A Soaring Impact on Biotechnology
From a technology application standpoint, the company's
significant impact was unlocking the data generated from
next-generation sequencing with minimal loss, that is,
identifying just a few molecules of mutated tumor DNA
from an entire tube of blood or what is known as “a needle
“
“
“
“
Cancer does not sleep, and neither will
we until we’ve accomplished our
mission of conquering cancer with data.
– Helmy Eltoukhy
33
October 2021

in a haystack” problem. Using the collective expertise of
Helmy and AmirAli, they solved two challenges to liquid
biopsy that were previously unsolved – sensitivity and
specificity.
With sensitivity, many technologies for sequencing in the
market were losing 95% of DNA before getting to the
sequencer. Guardant Health developed new chemistry that
successfully converted nearly 90% of the DNA in a tube of
blood, i.e., “the haystack”, to search for potentially a single
mutated tumor NDA, i.e., “a needle”.
The other problem was that sequencing technologies had a
high error rate of 1 in 100, masking with deep signals and
noise. The company's technology lowered the error rate by
a thousand-fold. So now, it sees a 1 in 3 million error rate
instead of 1 in 100, or in 1000, like other technologies.
Guardant Health continues to update its technology and
believes it is the highest performance technology on the
market today.
The Significance of Technology
The science of liquid biopsy has been around since the
1950s. Advancements in the last decade have been the
tipping point. There's been a confluence of different
genomic technologies, extraction methodologies, and high-
powered bioinformatic tools. The affordability of applying
next-generation sequencing to routine testing has enabled
Guardant Health to get much more sensitive and specific in
seeing the trace fragments of either DNA or proteins
contained within a tube of blood.
Until the company launched Guardant360 in 2014, off-the-
shelf DNA sequencing technologies were not only
unaffordable but not sensitive enough to see these trace
fragments in blood. Now their FDA-approved Guardant360
CDx provides doctors and their patients guideline-complete
genomic results with a turnaround time of seven days.
Setting Goals for the Long Run
Guardant Health focuses on what will have the greatest
impact on the most patients. AmirAli mentions that too
many families are losing loved ones every day to cancer, a
disease that remains the second leading cause of death.
AmirAli says, “At Guardant Health, our calling is to guard
the quality of human life from a debilitating disease and
offer patients more time. There are a lot of opportunities to
offer value to cancer patients, particularly around
increasing cancer screening rates across cancer types and
populations by bringing to market a simple blood test for
screening that is FDA approved and widely adopted. Even
with our test for complete genomic testing in patients with
advanced cancer, which informs potentially life-changing
treatment, these testing rates remain tragically low. We
cannot consider innovation alone success; we must
continue to increase adoption of the innovation to truly
make an impact on human health.”
Guardant Health’s informatics platform is a machine
learning platform, so the more data it gets, the better. “As
we continue to test more and more patients with cancer, at
all stages, we continue to exponentially increase our
knowledge about the disease. This not only fuels profound
innovations in the detection and monitoring of cancer, but
in treatments that may one day fight the disease before it is
even born. Cancer does not sleep, and neither will we until
we’ve accomplished our mission of conquering cancer with
data,” concludes Helmy.
We cannot consider innovation alone success; we must
continue to increase adoption of the innovation to truly
make an impact on human health.
– AmirAli Talasaz
‘
‘ ‘‘
| October 2021

Javier García
CEO : Viralgen Vector Core
Managing Director
& Founder : Columbus
Venture Partners
| October 2021

Javier García
Developing Strategies for Life-Saving Therapeutics
For over the past three decades, gene therapy has
consistently tried to improve its method to cure
diseases by developing several mechanisms.
Industry experts have researched meticulously to allow
doctors to treat a disorder by replacing genes. Javier
García, the CEO and Co-founder of Viralgen Vector
Core, has incorporated new technologies for medical
treatments that improve the health and lives of people.
In recent years, Javier García has led the strategy and
implementation of several projects that have marked the
forefront of the global biotechnology sector. He has become
a global reference as a manufacturer of AAVs for gene
therapy. This prompted its acquisition by Bayer in 2020 as
part of the AskBio acquisition, for $4 billion.
He is also the co-founder of Columbus Venture Partners, a
venture capital firm focused on driving the most disruptive
early science and its translation into the market. After the
success of Viralgen and other projects in the first two funds,
he has just launched a third one with 120 million euros.
Social responsibility is a key aspect of his activity. He is the
co-founder of Columbus Children's Foundation that started
in Spain in 2017 and expanded into the US in 2018. The
Foundation is specifically aimed at accelerating treatments
for children with ultra-rare diseases.
We at Insights Success caught up with Javier García to
know more about his journey and how Viralgen is meeting
the unmet needs for manufacturing gene therapies.
Below are the highlights of the interview:
Brief our audience about your journey as a business
leader until your current position at Viralgen. What
challenges have you had to overcome to reach where you
are today?
My main professional motivation has always been the
creation of value and transformation in the healthcare
industry. To devise and develop new projects that have a
real impact on people's lives and wellbeing has been a
constant. I started my first entrepreneurial experience in
1986.
I end up working for Eli Lilly for 25 years. I developed my
career in Information Technology and later in Business
Development. In IT, I lead the digital transformation of the
company in the R&D and commercial areas. As Vice
President of Business Development, I was involved at the
core of innovation acquisition and licensing.
In 2012, I became an independent consultant for biotech
companies and research centers. It was in those years that I
met my partner, Damià Tormo, with whom we decided to
create Columbus Venture Partners in 2015. We have now
three funds and more than $250M under management.
The main challenge I faced was to ensure that I really could
have the freedom to create a vision and execute it outside a
pharma company. Pharma companies are great places to
work and learn but leaving a pharma company from an
executive position and finding a meaningful place to make a
difference is not so simple. It requires discipline, a very
definitive commitment to learn and adapt to the world
without the protection of a large corporation.
Tell us something more about your company and its
mission and vision.
Viralgen was born in response to one of the most pressing
needs of the gene therapy market. There was a
manufacturing bottleneck that Viralgen helped to address
with unique technology, a world-class team, and extra
production capacity.
Viralgen's goal is to provide access to AAV gene therapy
solutions for people with genetic diseases. To achieve this,
its mission is to accompany its customers throughout the
entire process, from development to commercial
37
October 2021

manufacturing, so that they get the best quality product at
the right time and on the right scale and price.
Enlighten us on how you have made an impact in the
BioTech niche through your expertise in the market.
I believe that the key is to make a correct reading of what is
happening in the market, understand where it is heading,
anticipate events by assuming the risks that this implies.
There is great science in institutions, but there is not so
much knowledge in how to bring it to the market. Ensuring
people have access to this knowledge and to those who
have the experience is the key to success.
In a nutshell, I believe the role I play is to bring traditional
capital and intellectual capital to produce real and tangible
innovation. Today capital and knowledge need to be
brought together in ways never seen before. Smaller
organizations can leverage this new model better than the
larger ones and produce even greater results.
Boost
science for
a better life.
| October 2021

Describe in detail the values and the work culture that
drives your organization.
It is precisely Viralgen's corporate culture that enabled us to
attract highly qualified talent, suppliers, and customers. Our
culture is based on four core values: expertise, empathy,
humanity, and trust. Patients are at the center of our
decisions. That is the reason that quality is at the top of our
expectations.
This is manifested in the human approach of the
organization, and how we work with the Columbus
Children's Foundation to advance gene therapy programs
with no commercial interest through our contribution in
manufacturing.
We are the custodian of a potent technology that can
transform the lives of many people, and people that work at
Viralgen honor that commitment.
The commitment and pride of belonging that drive the
corporate culture is synthesized by this idea - inspired by
Dr. Jude Samulski (one of the fathers of gene therapy, and
founder of Askbio): "people at Viralgen don't only come to
work, but they come to change the world".
Where do you envision yourself to be in the long run,
and what are your future goals for Viralgen?
I will be developing innovative projects that drive a
relevant benefit for the wellbeing of people. I feel that this
is my vocation, my passion, and my place in the world.
Combining for-profit with non-for-profit makes lots of
sense, and I believe it is the new model for the pharma
industry and biotech.
I also believe we have to transform the world by giving
global access to cures. It is almost as wrapping non-for-
profit biotech as part of what we do. This is why we value
so much the work we are doing with the Columbus
Children´s Foundation. It is a reality that if we don´t do
anything about neglected diseases and global access nobody
will as we are the ones who understand the technology and
what we can do with it.
What would be your advice to budding entrepreneurs
who aspire to venture into the BioTech sector?
There are four areas that entrepreneurs need to develop: a
vision to establish a differential position on what they want
to achieve, leadership to ensure they know how to drive
39
toward the vision and face the challenges, courage to
overcome the barriers and deal with setbacks, and
compassion to be able to understand patient suffering and
urgency.
Anybody in this sector needs to be ready to get feedback,
network, and listen to perspectives from different angles.
Science is not everything; it is necessary but not sufficient. I
see many great projects failing because the leader didn't
take the right actions at the right time.
The final advice is that failure is not a negative thing. I
know that myself firsthand, and we need to take a different
attitude about that. Attrition of projects in biotech is high,
and failure is expected, but there will always be a great
project waiting, and the accumulated learning from failures
is very valuable.
|
October 2021

Jerry Lepore
CEO
MobileSmith Health
| October 2021

Jerry Lepore
Changing Healthcare, One Life at a Time
As CEO of MobileSmith Health, Jerry Lepore is
driving the healthcare mobile app development
company to change healthcare, one life at a time.
“We want to bring the patient in the healthcare ecosystem
to the center of the care circle using two approaches,” says
Lepore, who joined the MobileSmith Board of Directors in
2018 before being named CEO in January 2020. Lepore is a
serial entrepreneur who has founded, managed, and sold
more than a half-dozen companies.
“First, we want to engage patients in every aspect of their
health through technology and applications that are
necessary for them to be involved and manage their care
better,” Lepore says. “Second, we want to accumulate and
aggregate the data that a patient has to aid physicians and
other providers in driving better outcomes for that patient
and for patient populations while reducing overall costs.”
Upending the Traditional Patient Encounter
Founded in 2013, MobileSmith has targeted the key
healthcare delivery segments where patients struggle, such
as surgical procedure and adherence with pre-and post-
operative instruction compliance, and health literacy. The
company also provides innovative digital patient
experiences like indoor navigation and clinic “check-ins”
that directly improve patient satisfaction.
Everyone is familiar with the traditional patient experience,
where the patient often feels like an afterthought to the
clinician and the technology. How much time during a
patient visit is taken up by paperwork and ticking electronic
boxes on an electronic health records (EHR) system? How
much actual time does a clinician spend listening to the
patient?
“The usual patient visit is very one-sided, and lacks the
necessary collaboration to achieve better outcomes for
patients,” Lepore says. “So how do we flip it around?
MobileSmith provides a software solution that runs on a
platform that everyone has access to – a mobile device.
MobileSmith provides the means to engage with the
patient through mobile apps that save time, increase
patient adherence, and get them more involved in their
own care.”
Engaging Patients in their Own Health
The MobileSmith PeriOp Patient Adherence app benefits
both patients and providers, giving patients the tools to
manage their own pre-and post-surgical tasks while
reducing the administrative burden on practices. Surgeries
account for 60% of total hospital revenues, and a last-
minute cancellation can cost a hospital or ambulatory
surgical center more than $5,200 in lost revenue. In
addition, 60% of all same-day cancellations are deemed
preventable, caused by patients neglecting to fast,
take/stop certain medications, or show up on time.
By “prescribing” the PeriOp Patient Adherence app,
patients receive instructions through the app, with
notifications that pop up until each is ticked off a list.
Time to quit warfarin? Check. Has the patient reviewed
the pre-surgical instructions? Check. Remember the pre-
surgical hospital visit today? Check. The MobileSmith
app interacts with provider EHR systems, so staff can
monitor adherence and manage exceptions, rather than
calling every patient at every step of the pre-surgery
process.
Following surgery, the app contains the discharge and
after-care instructions in a readily available format,
instead of printed instructions that can be misplaced or
tossed out. Scheduled the follow-up visit? Check.
Changed the surgical dressing today? Check. Ready for
the first physical therapy session? Check.
41
|
October 2021

“Our perioperative applications are a set of alerts,
management capabilities, and instructions that can be
adhered to by the patient on a daily basis or even hourly
basis, with responses captured and presented to the clinical
staff so that they can monitor what's taking place
throughout the preparation period, the day of, and the post-
op period to ensure a better outcome for the patient,”
Lepore says.
MobileSmith Health apps also can integrate patient-
reported data from fitness trackers, blood monitoring
systems and more into EMRs so providers can review that
information. The company is in the final development
stages of apps that help patients monitor and manage such
chronic conditions as diabetes and chronic obstructive
pulmonary disease (COPD), with a rollout expected in early
2022.
‘Pick Something You Love’
Healthcare’s move to value-based care and improving the
outcomes of patient populations play well to MobileSmith’s
strengths as a healthcare mobile app developer. People of
all ages are accustomed to banking, shopping, browsing,
and more on their mobile devices, so managing their
healthcare is a natural progression.
In leading MobileSmith Health, Lepore has discovered a
personal and professional sweet spot. “Two-thirds of my
career has been more entrepreneurial in nature, and I
decided to focus in areas that really excite me, such as
education, child services, and healthcare,” Lepore says.
“In finding a career, you absolutely have to pick something
you love. If you don't, then you're not going to work at it
every minute of every day with a passion that you need to,
and that's what an entrepreneur needs to do.”
“I've always felt that if I was focusing on things that were
important to me and important to others, versus focusing on
a job and a career, then I would be happier and more
productive,” Lepore says. “MobileSmith Health is smack
dab in the middle of the healthcare space at a great time, so
it's a fantastic fit.”
We are connecting
healthcare providers to
their patients and their
patients to their health
to improve clinical
outcomes and the
overall patient journey.
‘‘
‘‘
| October 2021

Positive Impact
| October 2021

Leading
with Right Skills
S
trong leadership is essential in every field to
accomplish something worthy for the welfare of
human society and higher purposes. Ensuring the
good health of people is the most important aspect of any
civilized society. Good healthcare should be the first
priority above all because no one will be able to contribute
their best to the world without good health. To ensure good
health in all people, there is a need for a strong healthcare
system under the able guidance of good healthcare leaders.
Institution or any industry or field is only as strong as the
leaders in that field. The Healthcare sector comes under the
essential services, and the importance of strong leadership
in this sector is huge, as this field directly deals with the
most important aspect of health in the lives of everyone,
and there is no room for any complacency and negligence.
Below are some of the necessary skills every healthcare
leader should have:
Ÿ Emotional Intelligence: Healthcare leaders should be
emotionally intelligent to make a positive difference in
the lives of people. They should connect with people by
understanding their issues and trying to resolve them by
using all their assets. They should lead by balancing
compassion and efficiency. Compassion for the public
and efficiency in the profession is the hallmark of good
healthcare leaders.
Ÿ Good communication skills: Healthcare leaders have
to come across a lot of people, and they should have the
ability to effectively communicate their ideas and
thoughts to everyone.
Ÿ Educating Others: Healthcare leaders should educate
people by spreading awareness about important factors
that play a significant role in maintaining good health.
They can do this through the medium of blogs or
articles. They can make a conscious change in the lives
of people by educating them on the habits and behaviors
that are more favorable for good health.
Ÿ Innovative Approach: Healthcare leaders should have
an innovative approach. They should be courageous
enough to break the status quo and implement
innovative ideas in their organization to improve
healthcare services. They should step outside their
comfort zones and should be open to new processes and
implementing new technologies for the better delivery
of healthcare services.
Ÿ Good Decision-making ability: Healthcare leaders
should have good decision-making ability. They should
have enough situational intelligence and presence of
mind to take high-value decisions even at the spur of the
moment. They should take logical, thoughtful,
analytical, and calculative decisions.
Ÿ Being Judicious: Complacency in any profession is
dangerous, and they should promote the approach of not
being complacent but being judicious in the profession.
Ÿ Having Character and Competence: Healthcare
leaders should have good character and the right
intentions to be able to make a positive contribution to
the lives of many people. They should lead with a touch
of human sensitivity and a welfare approach. They
should be competent to deliver greater results.
Above are some of the necessary skills for being a
sound healthcare leader and making a valuable
contribution to people's lives.
In a nutshell, we can say that healthcare leaders should
talk empathetically, demonstrate credibility and
accountability by setting exemplary standards, and
contribute to quality, affordable, and accessible care.
45
October 2021

Jim Bob Ward
Empowering Clinical Teams with Innovative
and End User Friendly Solutions
The healthcare industry has been experiencing a bout
of turbulence in the past year and a half but has
been on the upswing. Many organizations were
dealt the arduous task to meet the growing demands for
powerful performance analytics to manage clinical trials. It
was also essential for them to find a way to eliminate the
need for a lengthy, complex implementation process. With
the help of technological advancements, industry experts
came up with solutions that were as straightforward as
possible. Jim Bob Ward, the CEO and President of
Datatrak International, Inc. founded a successful solution
to make clinical trials flexible by enhancing its applications
to virtually engage patients and staff.
Jim Bob is an investment activist, passionate entrepreneur,
and pioneer responsible for developing one of the Internet’s
first cloud-based development platforms in 1994. He is the
original inventor of the Datatrak SaaS Cloud platform. His
30 years of experience has created cloud-based
technologies and businesses within the Life Science,
Market Investment, Insurance, Mortgage, Real Estate, and
Agricultural industries.
In an interview with Insights Success, Jim Bob shares his
entrepreneurial journey and his contribution to the
healthcare industry through Datatrak.
Below are the highlights of the interview:
Give us a brief overview of your position at Datatrak
International and your journey since the inception of
the company.
Datatrak was the first clinical research electronic data
capture (EDC) company established back in 1991. By the
mid-2000s, the software had reached the end of its life
cycle as the industry migrated to the ‘Net for global
software service’ delivery. In 2006, Datatrak acquired my
company Clickfind as their cloud-based standard.
Technically, Clickfind eClinical was a single login, multi-
tenant and multi-lingual, Software-as-a-Service (SaaS)
platform for clinical research. With my IP, we were the only
company to defeat Datasci’s industry-wide litigation. We
were revolutionaries defining early CTMS and EDC,
complete with a visual designer, randomization, medical
coding, supply management, and remote ECG and image
capture. I left the company in 2008 to raise four boys
backpacking the world. In 2015, I met Alex Tabatabai,
whose fund was heavily invested in Datatrak. Mutual
frustration and excitement for the future led to a proxy
challenge and the two of us taking on Datatrak in 2016.
After replacing the board and leadership, we refocused the
company on innovation, which brought us to profitability
and NextGen solutions for a post-pandemic world.
Please list the popular services that make your company
stand out from the competition.
The one and only Datatrak difference is our enterprise
platform that unifies team collaboration with vertical
integration across applications to prevent service delivery
gaps that delay clinical trials. With the centralization of
clinical trial data, our system provides an enhanced
experience for all parties involved, from decision-making to
site satisfaction.
As the CEO, what is your opinion on the impact of the
current pandemic on the Computer Software Industry?
COVID-19 created the largest recession since the 1930’s
depression. The nature of social isolation brought about
cultural disorder and inequity that pitted individual rights
against public safety needs. Pandemic fears stopped patient
site visits, disrupting 70% of global clinical trials across
194 countries. The economic results would have been
devastating without the FDA’s guidance that opened the
door to emerging smart technology for remote patient data
capture. Today, their guidance had advanced the industry to
adopt team collaboration platforms with AI predictive
analytics for modern “hybrid” data capture from sites, labs,
and remote patients.
What is your thought on the necessity of a positive work
culture? In what ways do you implement it at your
organization?
People are the number one asset to an organization. A
corporate-owned culture requires equity and transparency
| October 2021

Jim Bob Ward
CEO and President
Datatrak International
49
|
October 2021

without unnecessary barriers to communications. Datatrak
adopted a remote workforce model early on to provide
flexibility for our employees. However, the fear of isolation
encouraged us to put in place employee programs with
incentives and recognition.
What is your thought on the necessity for businesses to
align their offerings with newer technological
developments, especially when it comes to creating
digital software for clinical trials?
I truly believe “innovate or die” is still the rule in today’s
competitive global economy. Technology for clinical trials
must be self-configurable with unlimited scalability to meet
the changing needs of organizations working from the
cloud. The result must be focused on enabling global team
collaboration for the benefit of patient advocacy.
In what ways have you contributed to the community?
If given a chance, what change would you bring into
making eClinical Solutions Simple?
We simplify the complex by streamlining workflows to
reduce costly service delivery gaps between clinical
applications. There is no longer a need or desire for an array
of different systems and integrations when one platform can
do it all. One example is that our platform is able to
anonymize and import medical images directly into EDC
for radiologist assessment, adjudication and even import
DICOM data directly into electronic case report forms
(eCRFs) for the last mile to FDA submission. Simple things
can cut the setup and training time between redundant PAC
to EAS by 50%. The same is true for delivering
decentralized trials that automatically integrate smart app
data with hybrid site and core lab data. Our latest challenge
is to invent new AI models that can learn from predictable
outcomes to provide intelligent workflows within our
eClinical solutions.
If given a chance, what change would you bring in
strengthening the progress of the Life Science industry?
Datatrak has provided innovative technology and
unmatched services, aiding our customers on their journeys
to increase efficiencies and reduce error rates. In addition,
our clients can move on to create unmeasurable benefits for
people in need with life-changing discoveries. We can
strengthen progress by working with pharma, medical
device, and biotech leaders as technology partners focused
on patient efficacy. Datatrak is constantly innovating and
looking to the future to ensure that we are prepared so that
our partners and clients can bring breakthrough therapies to
market faster.
In your opinion, what could be the future of Clinical
Data Management? And how are you strategizing
Datatrak International operations for that future?
The COVID-19 pandemic changed everything. Clinical
Research and Development will be driven by Big Data
Analytics and AI from the historical site, lab, patient, and
device-driven data that’s growing exponentially in real-
time. The magnitude and scale are beyond perception,
requiring a new generation of data scientists and machine
learning models to predict patterns and trends, leading to
better planning, data analysis, and faster trial results. It’s the
future, and with 18 years of structured clinical data, we are
developing performance algorithms, dashboards, and design
tools to enable our clients to derive data visualizations for
forecasting, trends, statistics, and much more.
“Dedicate
yourself to the
economics of
math and
sciences and
invent your
future.”
TM
| October 2021

Jon Z
Jon Zimmerman
CEO
Holon Solutions
| October 2021

Zimmerman
Combining Technology and Innovation to
Streamline Healthcare
alue-based care is here to stay. Many healthcare
Vorganizations are now migrating from a fee-for-
service to a value-based care model. This transition
requires leaders who can bring strategies to life while
keeping an eye on the competition and ready to lead the
change.
Jon Zimmerman, the CEO of Holon Solutions, is one
such strategic leader who has a successful track record for
helping healthcare organizations accelerate their transition
to value-based care.
An industry veteran, Jon is recognized for his expertise and
commitment to advancing health outcomes by delivering
the most precise health information to the right stakeholders
at the right time with the help of technology. He is
committed to overcoming the hurdles to effective health
information sharing with the help of technology.
As CEO, Zimmerman is responsible for setting the strategic
direction for Holon while enabling, empowering and
encouraging the Team to deliver for and with the
Customers.
Delivering Exceptional Value to Customers and
Partners
Jon became the CEO of Holon Solutions in October of
2019. Since then, Holon Solutions has solidified and
expanded its technology platform, including getting two
major patents awarded; built a team of highly scaled cross-
functional leaders with a shared vision and passion for
serving customers and improving healthcare; signed and
implemented several strategic distributors, customers, and
partners; and built its strategic growth plan to deliver
exponential value to its customers and partners.
Providing Comprehensive Technology Platform
Holon is on a mission to improve health for everyone
through precision information delivery that maximizes
clinical and financial outcomes with sustainable engagment.
Its technology platform incorporates:
Ÿ Contextual, Workflow-Driven, Personalized Experiences
for Each User
Ÿ Delivering multiple desired Knowledge Sources
Simultaneously
Ÿ Designed and Built to Complement and Extend Sponsors
and Customers Current Systems
Ÿ With complementary adoption services and operational
analytics for a virtuous cycle of continuous improvement
So, Holon's sponsors and users can reduce burden to:
Ÿ Close Care Gaps to Meet Measures
Ÿ Create Accurate Risk Scores
Ÿ Improve Network Integrity
Ÿ Coordinate Community Resources
Ÿ Improve Lab Order Coding
Ÿ Automate Authorizations
Ÿ Enable patients to engage in practices
Implement Value-based Care
According to Jon, the pandemic has permanently changed
healthcare and the healthcare industry. Telehealth has
accelerated 5-10 years. Health equity disparities have
become much more evident. Personal responsibilities and
choices have become part of the national dialogue. The
challenges of unsustainable burden while implementing
value-based care in a data-fragmented environment have
risen to the surface as an area that must be addressed
immediately.
Making Healthcare Better for Everyone
The leadership team at Holon Solutions has seen
extraordinary advancements in the use of analytics and
analytic support tools to help them better understand what
the best action is to take for anyone anywhere. It has also
seen great advancements in patient engagement, remote
53
|
October 2021

access, such as telehealth, and remote patient monitoring to
enable more care to go to people versus more people having
to go to care.
Jon mentions that they are starting to realize the critical
importance of "whole-person care" via the rising
recognition of the factors of Social Determinants of Health
to enable people to achieve better health via more
comprehensive support. Yet, these advancements will
underachieve their potential if they are not organized and
implemented in a coordinated fashion to facilitate broad
adoption and maximize value for the care teams and their
patients.
Delivering High-impact Knowledge and Collaborative
Functionality
In Jon's opinion, our healthcare ecosystem is highly
fragmented, difficult to navigate, and increasingly complex.
Through patented technology, Holon first senses what a
user is trying to accomplish for and/or with whom. The
software then determines and delivers additional
information or adjunct capability that helps them
accomplish the right task with less work and better
outcomes.
Holon Solutions is continually expanding its sensing,
content/function-sourcing, and information logistics
capabilities so it can deliver high-impact knowledge and
collaborative functionality to more users so they can focus
on the tasks, not navigating an impossibly snarled
ecosystem. Jon states that machines can and should
simplify navigation so people can do their best and most
important work with minimal disruptions.
Having Inspired and Shared Purpose
Talking about the significance of positive work culture, Jon
mentions that it is a must-have to ensure any winning
business. Holon's positive work culture stems from having
an inspired and shared purpose of delivering customer value
with respect and support for all individuals on the team
built upon a foundation and practice of collaboration with
transparency. The Holon team enjoys enabling, empowering
and encouraging each other to do our best together for our
customers every day.
| October 2021

It's about Prioritizing Needs of Stakeholders and
Meeting them
We asked Jon which is the best way to meet today's and
tomorrow's challenges for urgent needs coming our way, to
which he answers, "Developing empathetic understanding
is key. Identify and engage stakeholders thoughtfully to
understand their goals, barriers, and accelerators to
achieve them. Align the stakeholders objectives with those
of their co-dependent colleagues. Carefully prioritize their
needs. Ensure adoption and integrate the desired
capabilities into the user's workﬂows in a way that helps
them. And continuously measure, extend, and improve the
impact over time”
A Note to Aspiring Leaders
In his advice to emerging healthcare leaders, Jon says,
"Build a foundation of operational understanding of
healthcare. Always start with understanding a Stakeholder's
"Why" they need a solution. Focus on real, tangible,
achievable, and measurable impacts.”
He also adds, "Look broadly at the technology landscape to
develop the art of the possible and practical. Listen smart,
work fast, design for adoption, enable, and measure
customer achievements."
“We are changing the interoperability and
information access paradigms with patented
technology that delivers curated, precise patient
information — from any health IT system —
into the right hands at the right time.”
55
October 2021

Top 10 pioneering leaders redefining healthcare 2021(8) compressed

Top 10 pioneering leaders redefining healthcare 2021(8) compressed

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Similar a Top 10 pioneering leaders redefining healthcare 2021(8) compressed

Similar a Top 10 pioneering leaders redefining healthcare 2021(8) compressed (20)

Más de insightssuccess2

Más de insightssuccess2 (20)

Último

Último (20)

Top 10 pioneering leaders redefining healthcare 2021(8) compressed